Identification

Name
Everolimus
Accession Number
DB01590
Type
Small Molecule
Groups
Approved
Description

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Structure
Thumb
Synonyms
  • 40-O-(2-hydroxyethyl)-rapamycin
External IDs
RAD 666 / RAD-001 / RAD-666 / RAD001 / SDZ RAD / SDZ-RAD
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AfinitorTablet5 mgOralNovartis Europharm Limited2009-08-03Not applicableEu
AfinitorTablet7.5 mg/1OralNovartis2011-07-29Not applicableUs
AfinitorTablet2.5 mgOralNovartis2011-08-05Not applicableCanada
AfinitorTablet10 mgOralNovartis Europharm Limited2009-08-03Not applicableEu
AfinitorTablet5 mg/1OralNovartis2009-03-31Not applicableUs
AfinitorTablet10 mgOralNovartis Europharm Limited2009-08-03Not applicableEu
AfinitorTablet2.5 mgOralNovartis Europharm Limited2009-08-03Not applicableEu
AfinitorTablet7.5 mgOralNovartis2016-04-05Not applicableCanada
AfinitorTablet2.5 mg/1OralNovartis2010-07-09Not applicableUs
AfinitorTablet5 mgOralNovartis Europharm Limited2009-08-03Not applicableEu
International/Other Brands
Votubia (Novartis)
Categories
UNII
9HW64Q8G6G
CAS number
159351-69-6
Weight
Average: 958.24
Monoisotopic: 957.581356357
Chemical Formula
C53H83NO14
InChI Key
HKVAMNSJSFKALM-GKUWKFKPSA-N
InChI
InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
IUPAC Name
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
SMILES
[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC

Pharmacology

Indication

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Everolimus is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake.

TargetActionsOrganism
ASerine/threonine-protein kinase mTOR
inhibitor
Human
Absorption

In patients with advanced solid tumors, peak everolimus concentrations are reached 1 to 2 hours after administration of oral doses ranging from 5 mg to 70 mg. Following single doses, Cmax is dose-proportional between 5 mg and 10 mg. At doses of 20 mg and higher, the increase in Cmax is less than dose-proportional, however AUC shows dose-proportionality over the 5 mg to 70 mg dose range. Steady-state was achieved within 2 weeks following once-daily dosing. Dose Proportionality in Patients with SEGA (subependymal giant-cell astrocytomas) and TSC (tuberous sclerosis complex): In patients with SEGA and TSC, everolimus Cmin was approximately dose-proportional within the dose range from 1.35 mg/m2 to 14.4 mg/m2.

Volume of distribution

The blood-to-plasma ratio of everolimus is 17% to 73%.

Protein binding

~ 74% in both healthy patients and those with moderate hepatic impairment.

Metabolism

Everolimus is a substrate of CYP3A4 and PgP (phosphoglycolate phosphatase). Three monohydroxylated metabolites, two hydrolytic ring-opened products, and a phosphatidylcholine conjugate of everolimus were the 6 primary metabolites detected in human blood. In vitro, everolimus competitively inhibited the metabolism of CYP3A4 and was a mixed inhibitor of the CYP2D6 substrate dextromethorphan.

Route of elimination

After a single dose of radiolabeled everolimus was given to transplant patients receiving cyclosporine, the majority (80%) of radioactivity was recovered from the feces and only a minor amount (5%) was excreted in urine.

Half life

~30 hours.

Clearance

Following a 3 mg radiolabeled dose of everolimus, 80% of the radioactivity was recovered from the feces, while 5% was excreted in the urine.

Toxicity

IC50 of 0.63 nM.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Everolimus.Experimental
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Everolimus.Experimental, Investigational
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Everolimus is combined with 2-Methoxyethanol.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Everolimus.Investigational
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Everolimus.Experimental
4-hydroxycoumarinThe serum concentration of 4-hydroxycoumarin can be increased when it is combined with Everolimus.Experimental
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Everolimus.Investigational
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Everolimus.Experimental
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Everolimus.Experimental
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Everolimus.Experimental
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Everolimus.Approved
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Everolimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.Investigational
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Everolimus.Experimental
9-MethylguanineThe metabolism of 9-Methylguanine can be decreased when combined with Everolimus.Experimental
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Everolimus.Approved
AbemaciclibThe serum concentration of Everolimus can be increased when it is combined with Abemaciclib.Approved, Investigational
AbetimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Abetimus.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Everolimus.Approved, Investigational
AcefyllineThe metabolism of Acefylline can be decreased when combined with Everolimus.Experimental
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Everolimus.Approved, Investigational
AcetaminophenThe serum concentration of Everolimus can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Everolimus.Approved, Investigational, Withdrawn
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Everolimus.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Everolimus.Experimental
ActeosideThe risk or severity of adverse effects can be increased when Everolimus is combined with Acteoside.Investigational
AcyclovirThe metabolism of Acyclovir can be decreased when combined with Everolimus.Approved
AdalimumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Adalimumab.Approved
AfatinibThe serum concentration of Everolimus can be increased when it is combined with Afatinib.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Everolimus is combined with Afelimomab.Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Everolimus.Experimental, Investigational
AlbendazoleThe serum concentration of Everolimus can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideThe therapeutic efficacy of Albiglutide can be decreased when used in combination with Everolimus.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Alclometasone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Everolimus is combined with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Everolimus is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Everolimus can be increased when it is combined with Alectinib.Approved, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Everolimus is combined with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Alemtuzumab.Approved, Investigational
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Everolimus.Approved, Illicit
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Everolimus.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Everolimus.Approved, Illicit, Investigational
AltretamineThe risk or severity of adverse effects can be increased when Everolimus is combined with Altretamine.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Everolimus is combined with Amcinonide.Approved
AMG-222The therapeutic efficacy of AMG-222 can be decreased when used in combination with Everolimus.Investigational
AmiodaroneThe serum concentration of Everolimus can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Everolimus can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Everolimus can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Everolimus can be increased when it is combined with Amoxapine.Approved
AmprenavirThe serum concentration of Everolimus can be increased when it is combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Everolimus can be increased when it is combined with Amsacrine.Approved, Investigational
AnagliptinThe therapeutic efficacy of Anagliptin can be decreased when used in combination with Everolimus.Investigational
AnakinraThe risk or severity of adverse effects can be increased when Everolimus is combined with Anakinra.Approved
AnnamycinThe serum concentration of Everolimus can be increased when it is combined with Annamycin.Investigational
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Everolimus.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Everolimus.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Everolimus.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Everolimus is combined with Antilymphocyte immunoglobulin (horse).Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Everolimus is combined with Antithymocyte immunoglobulin (rabbit).Approved
ApalutamideThe serum concentration of Everolimus can be decreased when it is combined with Apalutamide.Approved, Investigational
ApremilastThe risk or severity of adverse effects can be increased when Everolimus is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Everolimus can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Everolimus is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Everolimus can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Everolimus.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Everolimus can be increased when it is combined with Atazanavir.Approved, Investigational
AtorvastatinThe serum concentration of Everolimus can be increased when it is combined with Atorvastatin.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Everolimus is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Everolimus.Approved
AzelastineThe serum concentration of Everolimus can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Everolimus can be increased when it is combined with Azithromycin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Everolimus.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Everolimus.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Everolimus.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Everolimus.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Everolimus.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Everolimus.Approved
Bafilomycin A1The serum concentration of Everolimus can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Everolimus can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Everolimus.Investigational
BamifyllineThe metabolism of Bamifylline can be decreased when combined with Everolimus.Experimental
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Everolimus.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Everolimus.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Everolimus is combined with Beclomethasone dipropionate.Approved, Investigational
BegelomabThe risk or severity of adverse effects can be increased when Everolimus is combined with Begelomab.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Everolimus is combined with Belatacept.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Belimumab.Approved
BelinostatThe risk or severity of adverse effects can be increased when Everolimus is combined with Belinostat.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Everolimus.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Benazeprilat.Experimental
BendamustineThe risk or severity of adverse effects can be increased when Everolimus is combined with Bendamustine.Approved, Investigational
BenfluorexThe therapeutic efficacy of Benfluorex can be decreased when used in combination with Everolimus.Investigational, Withdrawn
BenzquinamideThe serum concentration of Everolimus can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe serum concentration of Everolimus can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Everolimus can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Betamethasone.Approved, Vet Approved
BevacizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Bevacizumab.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Everolimus is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Everolimus can be increased when it is combined with Bicalutamide.Approved
Biricodar dicitrateThe serum concentration of Everolimus can be increased when it is combined with Biricodar dicitrate.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Everolimus is combined with Bleomycin.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Everolimus is combined with Blinatumomab.Approved, Investigational
BoceprevirThe serum concentration of Everolimus can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Everolimus is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Everolimus can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Everolimus.Approved
Brefeldin AThe serum concentration of Everolimus can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Everolimus is combined with Brentuximab vedotin.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Briakinumab.Investigational
BrigatinibThe serum concentration of Everolimus can be decreased when it is combined with Brigatinib.Approved, Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Brodalumab.Approved, Investigational
BromotheophyllineThe metabolism of Bromotheophylline can be decreased when combined with Everolimus.Approved
BudesonideThe risk or severity of adverse effects can be increased when Everolimus is combined with Budesonide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Everolimus.Investigational, Withdrawn
BufyllineThe metabolism of Bufylline can be decreased when combined with Everolimus.Experimental
BuprenorphineThe serum concentration of Everolimus can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Everolimus.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Everolimus is combined with Busulfan.Approved, Investigational
CabazitaxelThe serum concentration of Everolimus can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Everolimus.Approved
CafedrineThe metabolism of Cafedrine can be decreased when combined with Everolimus.Investigational
CaffeineThe serum concentration of Everolimus can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Everolimus can be increased when it is combined with Canagliflozin.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Canakinumab.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Everolimus is combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Everolimus can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Everolimus can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Everolimus is combined with Carboplatin.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Everolimus.Experimental
CarfilzomibThe risk or severity of adverse effects can be increased when Everolimus is combined with Carfilzomib.Approved, Investigational
CarmegliptinThe therapeutic efficacy of Carmegliptin can be decreased when used in combination with Everolimus.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Everolimus is combined with Carmustine.Approved, Investigational
CarvedilolThe serum concentration of Everolimus can be increased when it is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Everolimus is combined with Castanospermine.Experimental
CefoperazoneThe serum concentration of Everolimus can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Everolimus can be increased when it is combined with Ceftriaxone.Approved
CeritinibThe serum concentration of Everolimus can be increased when it is combined with Ceritinib.Approved
CerivastatinThe excretion of Cerivastatin can be decreased when combined with Everolimus.Approved, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Everolimus is combined with Certolizumab pegol.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Everolimus is combined with Chlorambucil.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Everolimus is combined with Chloramphenicol.Approved, Vet Approved
ChloroformThe serum concentration of Everolimus can be increased when it is combined with Chloroform.Vet Approved
ChlorpromazineThe serum concentration of Everolimus can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Everolimus.Approved, Investigational
ChlorprothixeneThe serum concentration of Everolimus can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Everolimus is combined with Ciclesonide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Everolimus.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Cilazapril.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Everolimus.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Everolimus is combined with Cisplatin.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Everolimus.Approved, Investigational
ClarithromycinThe serum concentration of Everolimus can be increased when it is combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Everolimus is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Everolimus is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Clocortolone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Everolimus is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Everolimus can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Everolimus can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
CloprednolThe risk or severity of adverse effects can be increased when Everolimus is combined with Cloprednol.Experimental
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Everolimus.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Everolimus.Approved
ClotrimazoleThe serum concentration of Everolimus can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Everolimus is combined with Clozapine.Approved
CobicistatThe serum concentration of Everolimus can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Everolimus can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Everolimus can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Everolimus.Approved, Investigational
CorticotropinThe risk or severity of adverse effects can be increased when Everolimus is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Everolimus is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Everolimus is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Everolimus.Approved
CrizotinibThe serum concentration of Everolimus can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Everolimus can be increased when it is combined with Curcumin.Approved, Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Everolimus is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Everolimus can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Everolimus.Experimental
CytarabineThe risk or severity of adverse effects can be increased when Everolimus is combined with Cytarabine.Approved, Investigational
DabrafenibThe serum concentration of Everolimus can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Everolimus is combined with Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Everolimus can be increased when it is combined with Daclatasvir.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Everolimus.Investigational, Withdrawn
DactinomycinThe serum concentration of Everolimus can be increased when it is combined with Dactinomycin.Approved, Investigational
DanazolThe serum concentration of Everolimus can be increased when it is combined with Danazol.Approved
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Everolimus.Approved
DarunavirThe serum concentration of Everolimus can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Everolimus can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Everolimus can be increased when it is combined with Daunorubicin.Approved
DecitabineThe risk or severity of adverse effects can be increased when Everolimus is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Everolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Everolimus is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Delapril.Investigational
DelavirdineThe serum concentration of Everolimus can be increased when it is combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Everolimus is combined with Deoxyspergualin.Investigational
DesipramineThe serum concentration of Everolimus can be increased when it is combined with Desipramine.Approved, Investigational
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Everolimus.Approved
DesmethylsertralineThe serum concentration of Everolimus can be increased when it is combined with Desmethylsertraline.Experimental
DesonideThe risk or severity of adverse effects can be increased when Everolimus is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Desoximetasone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Everolimus is combined with Dexamethasone isonicotinate.Vet Approved
DexniguldipineThe serum concentration of Everolimus can be increased when it is combined with Dexniguldipine.Experimental
DexrazoxaneThe risk or severity of adverse effects can be increased when Everolimus is combined with Dexrazoxane.Approved, Withdrawn
DexverapamilThe serum concentration of Everolimus can be increased when it is combined with Dexverapamil.Experimental
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Everolimus.Approved
Diethyl etherThe serum concentration of Everolimus can be increased when it is combined with Diethyl ether.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Everolimus is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Everolimus.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Everolimus.Approved
DihydroergocornineThe serum concentration of Dihydroergocornine can be increased when it is combined with Everolimus.Approved
DihydroergocristineThe serum concentration of Dihydroergocristine can be increased when it is combined with Everolimus.Approved, Experimental
DihydroergocryptineThe serum concentration of Dihydroergocryptine can be increased when it is combined with Everolimus.Experimental
DiltiazemThe serum concentration of Everolimus can be increased when it is combined with Diltiazem.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Everolimus is combined with Dimethyl fumarate.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Everolimus is combined with Dinutuximab.Approved, Investigational
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Everolimus.Experimental
DipyridamoleThe serum concentration of Everolimus can be increased when it is combined with Dipyridamole.Approved
DisopyramideEverolimus may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Everolimus is combined with Docetaxel.Approved, Investigational
DofequidarThe serum concentration of Everolimus can be increased when it is combined with Dofequidar.Experimental, Investigational
DovitinibThe serum concentration of Everolimus can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Everolimus can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Everolimus can be increased when it is combined with Doxepin.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Everolimus is combined with Doxifluridine.Investigational
DoxofyllineThe metabolism of Doxofylline can be decreased when combined with Everolimus.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Everolimus is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Everolimus can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Everolimus can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Everolimus can be increased when it is combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Everolimus.Approved, Investigational
DuloxetineThe serum concentration of Everolimus can be increased when it is combined with Duloxetine.Approved
DutogliptinThe therapeutic efficacy of Dutogliptin can be decreased when used in combination with Everolimus.Investigational
EconazoleThe serum concentration of Everolimus can be increased when it is combined with Econazole.Approved
EculizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Eculizumab.Approved, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Efalizumab.Approved, Investigational
EfavirenzThe serum concentration of Everolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Everolimus can be increased when it is combined with Elacridar.Investigational
EmopamilThe serum concentration of Everolimus can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Enalaprilat.Approved
EnasidenibThe serum concentration of Everolimus can be increased when it is combined with Enasidenib.Approved, Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Everolimus.Experimental
EntecavirThe metabolism of Entecavir can be decreased when combined with Everolimus.Approved, Investigational
EnzalutamideThe serum concentration of Everolimus can be decreased when it is combined with Enzalutamide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Everolimus is combined with Epirubicin.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Everolimus.Approved
EribulinThe risk or severity of adverse effects can be increased when Everolimus is combined with Eribulin.Approved, Investigational
ErlotinibThe serum concentration of Everolimus can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Everolimus can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsomeprazoleThe serum concentration of Everolimus can be increased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Everolimus.Approved, Illicit
EstramustineThe serum concentration of Everolimus can be increased when it is combined with Estramustine.Approved, Investigational
EtamiphyllineThe metabolism of Etamiphylline can be decreased when combined with Everolimus.Experimental
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Everolimus.Approved, Investigational
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Everolimus.Withdrawn
EtoposideThe serum concentration of Everolimus can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Everolimus can be decreased when it is combined with Etravirine.Approved
EvogliptinThe therapeutic efficacy of Evogliptin can be decreased when used in combination with Everolimus.Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Everolimus.Approved, Investigational
FelodipineThe serum concentration of Everolimus can be increased when it is combined with Felodipine.Approved, Investigational
FenethyllineThe metabolism of Fenethylline can be decreased when combined with Everolimus.Approved
FenofibrateThe serum concentration of Everolimus can be increased when it is combined with Fenofibrate.Approved
FentanylThe serum concentration of Everolimus can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FingolimodThe risk or severity of adverse effects can be increased when Everolimus is combined with Fingolimod.Approved, Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Everolimus is combined with Floxuridine.Approved
FlucloroloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluclorolone.Experimental
FluconazoleThe serum concentration of Everolimus can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe risk or severity of adverse effects can be increased when Everolimus is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Everolimus is combined with Fludarabine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Fludrocortisone.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Everolimus.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Everolimus is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Everolimus can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Everolimus can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluperolone.Experimental
FluphenazineThe serum concentration of Everolimus can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Everolimus is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Everolimus can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Everolimus is combined with Fluticasone propionate.Approved
FluvastatinThe excretion of Fluvastatin can be decreased when combined with Everolimus.Approved
FluvoxamineThe serum concentration of Everolimus can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormocortalThe risk or severity of adverse effects can be increased when Everolimus is combined with Formocortal.Experimental
FosamprenavirThe serum concentration of Everolimus can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Everolimus can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Everolimus can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurafyllineThe metabolism of Furafylline can be decreased when combined with Everolimus.Experimental
Fusidic AcidThe serum concentration of Everolimus can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Everolimus.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Everolimus is combined with Gallium nitrate.Approved, Investigational
GallopamilThe serum concentration of Everolimus can be increased when it is combined with Gallopamil.Investigational
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Everolimus.Approved, Investigational
GefitinibThe serum concentration of Everolimus can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Everolimus is combined with Gemcitabine.Approved
GemigliptinThe therapeutic efficacy of Gemigliptin can be decreased when used in combination with Everolimus.Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Everolimus is combined with Gemtuzumab ozogamicin.Approved, Investigational
GenisteinThe serum concentration of Everolimus can be increased when it is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Everolimus.Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Everolimus.Experimental
GlatiramerThe risk or severity of adverse effects can be increased when Everolimus is combined with Glatiramer.Approved, Investigational
GlecaprevirThe serum concentration of Everolimus can be increased when it is combined with Glecaprevir.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Everolimus.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Everolimus.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Everolimus.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Everolimus.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Everolimus.Approved, Investigational
GlisoxepideThe therapeutic efficacy of Glisoxepide can be decreased when used in combination with Everolimus.Investigational
GlyburideThe serum concentration of Everolimus can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Everolimus can be increased when it is combined with Glycerin.Approved, Investigational
GlycodiazineThe therapeutic efficacy of Glycodiazine can be decreased when used in combination with Everolimus.Approved, Investigational
GolimumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Golimumab.Approved
GosogliptinThe therapeutic efficacy of Gosogliptin can be decreased when used in combination with Everolimus.Investigational
Gramicidin DThe serum concentration of Everolimus can be increased when it is combined with Gramicidin D.Approved
GuanineThe metabolism of Guanine can be decreased when combined with Everolimus.Experimental
Guar gumThe therapeutic efficacy of Guar gum can be decreased when used in combination with Everolimus.Experimental
GusperimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Gusperimus.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Everolimus is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Halometasone.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Everolimus.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Everolimus.Approved, Withdrawn
HM-30181The serum concentration of Everolimus can be increased when it is combined with HM-30181.Experimental
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Everolimus.Approved
HycanthoneThe serum concentration of Everolimus can be increased when it is combined with Hycanthone.Approved, Investigational
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Everolimus.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroxychloroquineThe serum concentration of Everolimus can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Everolimus is combined with Hydroxyurea.Approved
HypericinThe risk or severity of adverse effects can be increased when Everolimus is combined with Hypericin.Investigational
HypoxanthineThe metabolism of Hypoxanthine can be decreased when combined with Everolimus.Experimental
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Everolimus is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Everolimus.Approved
IbuprofenThe serum concentration of Everolimus can be increased when it is combined with Ibuprofen.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Everolimus is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Everolimus can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Everolimus is combined with Ifosfamide.Approved
ImatinibThe serum concentration of Everolimus can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Imidapril.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Everolimus is combined with Imiquimod.Approved, Investigational
IndinavirThe serum concentration of Everolimus can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Everolimus can be increased when it is combined with Indomethacin.Approved, Investigational
InfliximabThe risk or severity of adverse effects can be increased when Everolimus is combined with Infliximab.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Everolimus.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Everolimus.Approved
Insulin BeefThe therapeutic efficacy of Insulin Beef can be decreased when used in combination with Everolimus.Approved
Insulin DegludecThe therapeutic efficacy of Insulin Degludec can be decreased when used in combination with Everolimus.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Everolimus.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Everolimus.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Everolimus.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Everolimus.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Everolimus.Approved
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Everolimus.Investigational
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Everolimus.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Everolimus is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Everolimus is combined with Interferon alfacon-1.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Everolimus is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Everolimus can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Everolimus can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe serum concentration of Everolimus can be increased when it is combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Everolimus can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Everolimus can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Everolimus can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Everolimus can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Everolimus can be increased when it is combined with Ivosidenib.Approved, Investigational
IxabepiloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Ixabepilone.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Everolimus.Approved
KetoconazoleThe serum concentration of Everolimus can be increased when it is combined with Ketoconazole.Approved, Investigational
KRP-104The therapeutic efficacy of KRP-104 can be decreased when used in combination with Everolimus.Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when Everolimus is combined with L-Phenylalanine.Approved, Investigational, Nutraceutical
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Everolimus.Experimental
LaniquidarThe serum concentration of Everolimus can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Everolimus can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Everolimus can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Everolimus can be increased when it is combined with Ledipasvir.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Everolimus.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Everolimus is combined with Lenalidomide.Approved
LetermovirThe serum concentration of Everolimus can be increased when it is combined with Letermovir.Approved, Investigational
LevofloxacinThe serum concentration of Everolimus can be increased when it is combined with Levofloxacin.Approved, Investigational
LidocaineThe serum concentration of Everolimus can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Everolimus can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Everolimus is combined with Linezolid.Approved, Investigational
LipegfilgrastimEverolimus may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Everolimus.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Lisinopril.Approved, Investigational
LisofyllineThe metabolism of Lisofylline can be decreased when combined with Everolimus.Investigational
LisurideThe serum concentration of Lisuride can be increased when it is combined with Everolimus.Approved, Investigational
LixisenatideThe therapeutic efficacy of Lixisenatide can be decreased when used in combination with Everolimus.Approved
LobeglitazoneThe therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Everolimus.Approved, Investigational
LobucavirThe metabolism of Lobucavir can be decreased when combined with Everolimus.Investigational
LomerizineThe serum concentration of Everolimus can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Everolimus can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Everolimus is combined with Lomustine.Approved, Investigational
LonafarnibThe serum concentration of Everolimus can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Everolimus can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Everolimus can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Everolimus can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Everolimus can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Everolimus can be increased when it is combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Everolimus is combined with Loteprednol.Approved
LovastatinThe serum concentration of Everolimus can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Everolimus can be increased when it is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Everolimus can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Everolimus can be decreased when it is combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe serum concentration of Lysergic Acid Diethylamide can be increased when it is combined with Everolimus.Illicit, Investigational, Withdrawn
MecaserminThe therapeutic efficacy of Mecasermin can be decreased when used in combination with Everolimus.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Everolimus is combined with Mechlorethamine.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Medrysone.Approved
MefloquineThe serum concentration of Everolimus can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Everolimus can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Everolimus is combined with Melengestrol.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Everolimus is combined with Melphalan.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Mepolizumab.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Meprednisone.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Everolimus is combined with Mercaptopurine.Approved
MetahexamideThe therapeutic efficacy of Metahexamide can be decreased when used in combination with Everolimus.Experimental
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Everolimus.Approved, Investigational, Withdrawn
MetergolineThe serum concentration of Metergoline can be increased when it is combined with Everolimus.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.Approved
MethadoneThe serum concentration of Everolimus can be increased when it is combined with Methadone.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Everolimus is combined with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Everolimus is combined with Methotrexate.Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Everolimus.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Methylprednisolone.Approved, Vet Approved
MethysergideThe serum concentration of Methysergide can be increased when it is combined with Everolimus.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Everolimus.Experimental
MetronidazoleThe serum concentration of Everolimus can be increased when it is combined with Metronidazole.Approved
MibefradilThe serum concentration of Everolimus can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Everolimus can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Everolimus can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Everolimus can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Everolimus.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Everolimus.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Everolimus is combined with Mitomycin.Approved
MitotaneThe serum concentration of Everolimus can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Everolimus can be increased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Everolimus is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Everolimus can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Moexipril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Everolimus is combined with Mometasone furoate.Approved, Vet Approved
MonensinThe serum concentration of Everolimus can be increased when it is combined with Monensin.Vet Approved
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Everolimus.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Everolimus.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Everolimus.Approved
NafcillinThe serum concentration of Everolimus can be decreased when it is combined with Nafcillin.Approved, Investigational
NaloxoneThe serum concentration of Everolimus can be increased when it is combined with Naloxone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Everolimus.Approved, Investigational
NBI-6024The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Everolimus.Investigational
NefazodoneThe serum concentration of Everolimus can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Everolimus is combined with Nelarabine.Approved, Investigational
NelfinavirThe serum concentration of Everolimus can be increased when it is combined with Nelfinavir.Approved
NeratinibThe serum concentration of Everolimus can be increased when it is combined with Neratinib.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Netoglitazone can be decreased when used in combination with Everolimus.Experimental
NetupitantThe serum concentration of Everolimus can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Everolimus can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Everolimus can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe serum concentration of Nicergoline can be increased when it is combined with Everolimus.Approved, Investigational
NigericinThe serum concentration of Everolimus can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Everolimus can be increased when it is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Everolimus can be increased when it is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Everolimus can be increased when it is combined with Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Everolimus.Approved
NisoldipineThe serum concentration of Everolimus can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Everolimus can be increased when it is combined with Nitrendipine.Approved, Investigational
NN344The therapeutic efficacy of NN344 can be decreased when used in combination with Everolimus.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Obinutuzumab.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Ocrelizumab.Approved, Investigational
OlaparibThe serum concentration of Everolimus can be increased when it is combined with Olaparib.Approved
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Everolimus.Experimental, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Omapatrilat.Investigational
OmarigliptinThe therapeutic efficacy of Omarigliptin can be decreased when used in combination with Everolimus.Investigational
OmeprazoleThe serum concentration of Everolimus can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
ONT-093The serum concentration of Everolimus can be increased when it is combined with ONT-093.Investigational
OsimertinibThe serum concentration of Everolimus can be increased when it is combined with Osimertinib.Approved
OuabainThe serum concentration of Ouabain can be increased when it is combined with Everolimus.Approved
OxaliplatinThe risk or severity of adverse effects can be increased when Everolimus is combined with Oxaliplatin.Approved, Investigational
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Everolimus.Approved
PaclitaxelThe serum concentration of Everolimus can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Everolimus can be increased when it is combined with Palbociclib.Approved, Investigational
PaliferminThe therapeutic efficacy of Palifermin can be decreased when used in combination with Everolimus.Approved
PaliperidoneThe serum concentration of Everolimus can be increased when it is combined with Paliperidone.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Everolimus is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Everolimus can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Paramethasone.Approved
ParitaprevirThe serum concentration of Everolimus can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe serum concentration of Everolimus can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Everolimus is combined with Pazopanib.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Everolimus is combined with Pegaspargase.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Everolimus is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Everolimus is combined with Peginterferon alfa-2b.Approved
PeldesineThe metabolism of Peldesine can be decreased when combined with Everolimus.Experimental, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Everolimus is combined with Pemetrexed.Approved, Investigational
PenciclovirThe metabolism of Penciclovir can be decreased when combined with Everolimus.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be decreased when used in combination with Everolimus.Approved, Investigational
PentazocineThe serum concentration of Everolimus can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentifyllineThe metabolism of Pentifylline can be decreased when combined with Everolimus.Experimental
PentobarbitalThe serum concentration of Everolimus can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Everolimus is combined with Pentostatin.Approved, Investigational
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Everolimus.Approved, Investigational
PergolideThe serum concentration of Pergolide can be increased when it is combined with Everolimus.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Perindopril.Approved
PerindoprilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Perindoprilat.Experimental
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Everolimus.Experimental
PethidineThe serum concentration of Everolimus can be increased when it is combined with Pethidine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Everolimus.Approved, Investigational, Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Everolimus.Approved, Investigational
PhenobarbitalThe serum concentration of Everolimus can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Everolimus.Approved, Investigational
PhenytoinThe serum concentration of Everolimus can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Everolimus can be increased when it is combined with Pibrentasvir.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Everolimus.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Everolimus can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Everolimus.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Everolimus is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Everolimus is combined with Pirfenidone.Approved, Investigational
PitavastatinThe excretion of Pitavastatin can be decreased when combined with Everolimus.Approved
PitolisantThe serum concentration of Everolimus can be decreased when it is combined with Pitolisant.Approved, Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Everolimus is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Everolimus can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Everolimus can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Everolimus is combined with Pralatrexate.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Everolimus.Approved, Investigational
PravastatinThe excretion of Pravastatin can be decreased when combined with Everolimus.Approved
PrazosinThe serum concentration of Everolimus can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Everolimus is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Everolimus can be increased when it is combined with Prednisone.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Everolimus is combined with Prednylidene.Experimental
PrimaquineThe serum concentration of Everolimus can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Everolimus can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Everolimus is combined with Procarbazine.Approved, Investigational
ProgesteroneThe serum concentration of Everolimus can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Everolimus can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Everolimus can be increased when it is combined with Propafenone.Approved
PropentofyllineThe metabolism of Propentofylline can be decreased when combined with Everolimus.Investigational
PropofolThe serum concentration of Everolimus can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropylthiouracilThe risk or severity of adverse effects can be increased when Everolimus is combined with Propylthiouracil.Approved, Investigational
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Everolimus.Experimental
ProtriptylineThe serum concentration of Everolimus can be increased when it is combined with Protriptyline.Approved
ProxyphyllineThe metabolism of Proxyphylline can be decreased when combined with Everolimus.Experimental
QuercetinThe serum concentration of Everolimus can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Everolimus can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinaprilat.Experimental
QuinidineThe serum concentration of Everolimus can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Quinine can be increased when it is combined with Everolimus.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Everolimus.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Everolimus is combined with Raltitrexed.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Ramipril.Approved
RamiprilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Ramiprilat.Experimental
RanitidineThe serum concentration of Everolimus can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Everolimus can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Everolimus can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Everolimus can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Everolimus.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Everolimus is combined with Rescinnamine.Approved
ReserpineThe serum concentration of Everolimus can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Everolimus can be increased when it is combined with Reversin 121.Experimental
RibociclibThe serum concentration of Everolimus can be increased when it is combined with Ribociclib.Approved, Investigational
RifampicinThe serum concentration of Everolimus can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Everolimus can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Everolimus can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Everolimus can be decreased when it is combined with Rifaximin.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Everolimus is combined with Rilonacept.Approved, Investigational
RilpivirineThe serum concentration of Everolimus can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe serum concentration of Everolimus can be decreased when it is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Everolimus.Investigational
RisperidoneThe serum concentration of Everolimus can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Everolimus can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Everolimus is combined with Rituximab.Approved
RivoglitazoneThe therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Everolimus.Experimental, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Everolimus.Approved
RolapitantThe serum concentration of Everolimus can be increased when it is combined with Rolapitant.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Everolimus.Approved, Investigational
RosuvastatinThe excretion of Rosuvastatin can be decreased when combined with Everolimus.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Everolimus.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Everolimus.Approved, Investigational
RucaparibThe serum concentration of Everolimus can be increased when it is combined with Rucaparib.Approved, Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Everolimus is combined with Ruxolitinib.Approved
SalinomycinThe serum concentration of Everolimus can be increased when it is combined with Salinomycin.Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Everolimus.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Everolimus.Approved
SaquinavirThe serum concentration of Everolimus can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Everolimus can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Everolimus.Approved
SecukinumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Secukinumab.Approved
SemaglutideThe therapeutic efficacy of Semaglutide can be decreased when used in combination with Everolimus.Approved, Investigational
SertralineThe serum concentration of Everolimus can be increased when it is combined with Sertraline.Approved
SiltuximabThe serum concentration of Everolimus can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Everolimus can be increased when it is combined with Simeprevir.Approved
SimvastatinThe excretion of Simvastatin can be decreased when combined with Everolimus.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Everolimus.Approved, Investigational
SirolimusThe metabolism of Sirolimus can be decreased when combined with Everolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Everolimus.Approved, Investigational
SorafenibThe serum concentration of Everolimus can be increased when it is combined with Sorafenib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Everolimus.Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Spirapril.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Everolimus.Investigational
StaurosporineThe serum concentration of Everolimus can be increased when it is combined with Staurosporine.Experimental
SteproninThe risk or severity of adverse effects can be increased when Everolimus is combined with Stepronin.Approved
StiripentolThe serum concentration of Everolimus can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Everolimus is combined with Streptozocin.Approved, Investigational
SulfadiazineThe therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Everolimus.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Everolimus.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Everolimus is combined with Sulfasalazine.Approved
SulfisoxazoleThe therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Everolimus.Approved, Vet Approved
SunitinibThe serum concentration of Everolimus can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantThe serum concentration of Everolimus can be increased when it is combined with Suvorexant.Approved, Investigational
TacrolimusThe serum concentration of Everolimus can be increased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Everolimus can be increased when it is combined with Tamoxifen.Approved
TariquidarThe serum concentration of Everolimus can be increased when it is combined with Tariquidar.Investigational
TaspoglutideThe therapeutic efficacy of Taspoglutide can be decreased when used in combination with Everolimus.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Everolimus.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Everolimus is combined with Tedizolid phosphate.Approved
TelaprevirThe serum concentration of Everolimus can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Everolimus can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Everolimus can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Temocapril.Experimental, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Everolimus is combined with Temozolomide.Approved, Investigational
TemsirolimusThe serum concentration of Everolimus can be increased when it is combined with Temsirolimus.Approved
TeneligliptinThe therapeutic efficacy of Teneligliptin can be decreased when used in combination with Everolimus.Investigational
TeniposideThe risk or severity of adverse effects can be increased when Everolimus is combined with Teniposide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Everolimus is combined with Tepoxalin.Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Everolimus.Approved, Withdrawn
TergurideThe serum concentration of Terguride can be increased when it is combined with Everolimus.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Everolimus is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Everolimus can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Everolimus can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Everolimus can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Everolimus can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Everolimus can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrandrineThe serum concentration of Everolimus can be increased when it is combined with Tetrandrine.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Everolimus.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Everolimus.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Everolimus.Approved, Investigational
TheodrenalineThe metabolism of Theodrenaline can be decreased when combined with Everolimus.Investigational
ThiotepaThe risk or severity of adverse effects can be increased when Everolimus is combined with Thiotepa.Approved, Investigational
TicagrelorThe serum concentration of Everolimus can be increased when it is combined with Ticagrelor.Approved
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Everolimus.Experimental
TioguanineThe risk or severity of adverse effects can be increased when Everolimus is combined with Tioguanine.Approved
TipifarnibThe serum concentration of Everolimus can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Everolimus can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Everolimus is combined with Tixocortol.Approved, Withdrawn
TocilizumabThe serum concentration of Everolimus can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Everolimus is combined with Tofacitinib.Approved, Investigational
TofacitinibEverolimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Everolimus.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Everolimus.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Everolimus.Approved
TopotecanThe risk or severity of adverse effects can be increased when Everolimus is combined with Topotecan.Approved, Investigational
ToremifeneThe serum concentration of Everolimus can be increased when it is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Everolimus is combined with Tositumomab.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Everolimus is combined with Trabectedin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Trandolapril.Approved
TrastuzumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Everolimus is combined with Trastuzumab emtansine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Everolimus is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Everolimus is combined with Triamcinolone.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Everolimus.Approved, Investigational
TrifluoperazineThe serum concentration of Everolimus can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Everolimus can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Everolimus is combined with Trifluridine.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Everolimus is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Everolimus can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Everolimus is combined with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Everolimus is combined with Trofosfamide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Everolimus.Investigational, Withdrawn
TroleandomycinThe serum concentration of Everolimus can be increased when it is combined with Troleandomycin.Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Everolimus.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Everolimus is combined with Ulobetasol.Approved
Uric AcidThe metabolism of Uric Acid can be decreased when combined with Everolimus.Experimental, Investigational
UstekinumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Ustekinumab.Approved, Investigational
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Everolimus.Approved, Investigational
ValganciclovirThe metabolism of Valganciclovir can be decreased when combined with Everolimus.Approved, Investigational
ValinomycinThe serum concentration of Everolimus can be increased when it is combined with Valinomycin.Experimental
ValomaciclovirThe metabolism of Valomaciclovir can be decreased when combined with Everolimus.Investigational
ValspodarThe serum concentration of Everolimus can be increased when it is combined with Valspodar.Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Everolimus.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Everolimus.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Vedolizumab.Approved
VelpatasvirThe serum concentration of Everolimus can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Everolimus.Approved
VenlafaxineThe serum concentration of Everolimus can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Everolimus can be increased when it is combined with Verapamil.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Everolimus.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Everolimus.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Everolimus is combined with Vilanterol.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Everolimus.Approved, Investigational
VinblastineThe serum concentration of Everolimus can be increased when it is combined with Vinblastine.Approved
VincamineThe serum concentration of Vincamine can be increased when it is combined with Everolimus.Experimental
VincristineThe risk or severity of adverse effects can be increased when Everolimus is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Everolimus is combined with Vindesine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Everolimus.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Everolimus is combined with Vinorelbine.Approved, Investigational
VoacamineThe serum concentration of Everolimus can be increased when it is combined with Voacamine.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Everolimus is combined with Voclosporin.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Everolimus.Approved, Investigational
VorapaxarThe serum concentration of Everolimus can be increased when it is combined with Vorapaxar.Approved
VorinostatThe risk or severity of adverse effects can be increased when Everolimus is combined with Vorinostat.Approved, Investigational
VoxilaprevirThe serum concentration of Everolimus can be increased when it is combined with Voxilaprevir.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Everolimus.Approved
WortmanninThe risk or severity of adverse effects can be increased when Everolimus is combined with Wortmannin.Experimental
XanthineThe metabolism of Xanthine can be decreased when combined with Everolimus.Experimental
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Everolimus.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Everolimus.Approved, Investigational
YohimbineThe serum concentration of Everolimus can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZidovudineThe risk or severity of adverse effects can be increased when Everolimus is combined with Zidovudine.Approved
ZiprasidoneThe serum concentration of Everolimus can be increased when it is combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Zofenopril.Experimental
ZomepiracThe serum concentration of Everolimus can be increased when it is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Everolimus can be increased when it is combined with Zosuquidar.Investigational
Food Interactions
Not Available

References

Synthesis Reference

EMA Report

General References
  1. Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA: Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem. 2001 Jun 7;44(12):2027-34. [PubMed:11384247]
  2. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11. doi: 10.1056/NEJMoa1001671. [PubMed:21047224]
  3. den Burger JC, Wilhelm AJ, Chahbouni A, Vos RM, Sinjewel A, Swart EL: Analysis of cyclosporin A, tacrolimus, sirolimus, and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry. Anal Bioanal Chem. 2012 Oct;404(6-7):1803-11. doi: 10.1007/s00216-012-6317-8. Epub 2012 Aug 17. [PubMed:22899246]
  4. Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ: Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol. 2013 May;71(5):1231-40. doi: 10.1007/s00280-013-2117-x. Epub 2013 Mar 3. [PubMed:23455452]
External Links
KEGG Drug
D02714
PubChem Compound
6442177
PubChem Substance
46505248
ChemSpider
21106307
ChEBI
68478
ChEMBL
CHEMBL1908360
Therapeutic Targets Database
DAP001223
PharmGKB
PA164746311
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Everolimus
ATC Codes
L01XE10 — EverolimusL04AA18 — Everolimus
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (548 KB)
MSDS
Download (220 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingOtherMeningiomas / Neurofibromatosis Type 2 / Vestibular Schwannomas1
0RecruitingSupportive CareHead and Neck Carcinoma / Salivary gland dysfunction / Xerostomia1
0RecruitingTreatmentDelayed Graft Function1
1Active Not RecruitingOtherNasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Cancers / Tumors, Solid1
1Active Not RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor-negative / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentCancer, Advanced / Tumors, Solid2
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentEsophageal Cancers1
1Active Not RecruitingTreatmentEsophageal Cancers / Neoplasms, Esophageal1
1Active Not RecruitingTreatmentFallopian Tube Cancer / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
1Active Not RecruitingTreatmentFumarate Hydratase (FH)-Deficient Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma / Renal Cell Adenocarcinoma / Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) / Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors / Triple-Negative Breast Cancer (TNBC) / Tumors Harboring Amplifications in the cMyc Gene / Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations / Tumors, Solid1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentLeukemias1
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Chronic Lymphocytic Leukemia1
1Active Not RecruitingTreatmentNeoplasms1
1Active Not RecruitingTreatmentNeoplasms / Neoplasms, Breast / Neoplasms, Kidney / Pancreatic Neuroendocine Neoplasms1
1Active Not RecruitingTreatmentNeuroendocrine Tumors2
1Active Not RecruitingTreatmentProstate Cancer2
1CompletedNot AvailableHepatic Insufficiency1
1CompletedNot AvailableTumors, Solid1
1CompletedTreatmentAdenoidcystic Carcinoma / Neuroendocrine Tumors / Solid Organ Malignancies1
1CompletedTreatmentAdvanced Cancer of the Esophagogastric Junction / Advanced Gastric Cancer1
1CompletedTreatmentAdvanced Gastric Cancer1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Breast Cancer (MBC) / Metastatic Renal Cell Carcinoma1
1CompletedTreatmentBladder Cancers / Renal Pelvis Cancer / Ureteral Cancer1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentCancer, Breast2
1CompletedTreatmentCancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCarcinoid Tumors / Neuroendocrine Tumors / Progressive Neuroendocrine Tumors of pancreatic origin2
1CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1CompletedTreatmentCentral nervous system neoplasms malignant NEC / Recurrent or Refractory Solid Tumors1
1CompletedTreatmentCholangiocarcinoma of the Gallbladder / Localized Gallbladder Cancer / Unresectable Gallbladder Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)1
1CompletedTreatmentEndometrial Cancers1
1CompletedTreatmentGastrin-Producing Neuroendocrine Tumor / Lung Carcinoid Tumor / Metastatic Digestive System Neuroendocrine Tumor G1 / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Polypeptide Tumor / Paraganglioma / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Merkel Cell Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Somatostatin-Producing Neuroendocrine Tumor / Stage III Merkel Cell Carcinoma / Stage IV Merkel Cell Carcinoma / Thyroid Gland Medullary Carcinoma1
1CompletedTreatmentGastrinoma / Glucagonoma / Insulinoma / Metastatic Gastrointestinal Carcinoid Tumor / Metastatic Pheochromocytoma / Non-Small Cell Lung Cancer Recurrent / Pancreatic Polypeptide Tumor / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Recurrent Melanoma / Recurrent Neuroendocrine Carcinoma of the Skin / Recurrent Pheochromocytoma / Renal Cell Cancer, Recurrent / Somatostatinoma / Stage III Neuroendocrine Carcinoma of the Skin / Stage IV Melanoma / Stage IV Non-Small Cell Lung Cancer / Stage IV Renal Cell Cancer / Thyroid Gland Medullary Carcinoma / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentHead & Neck Cancer1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentLocally Advanced Cervical Cancer1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Relapsed and/or Refractory Solid Tumors / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1CompletedTreatmentLung Cancers1
1CompletedTreatmentLung Cancers / Tumors, Solid1
1CompletedTreatmentLung Neuroendocrine Neoplasm1
1CompletedTreatmentMalignant Lymphomas1
1CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentMetastatic Clear Cell Renal Cancer1
1CompletedTreatmentMetastatic Colorectal Cancers1
1CompletedTreatmentMetastatic Renal Cell Carcinoma1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentNeoplasm Metastases1
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
1CompletedTreatmentNeoplasms, Brain / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Tumors1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRecurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Colon Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Basal Cell Carcinoma of the Lip / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Lymphoepithelioma of the Oropharynx / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Stage IVA Colon Cancer / Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Colon Cancer / Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Tongue Cancer1
1CompletedTreatmentRefractory Malignancy1
1CompletedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
1CompletedTreatmentRenal Cancers / Tumors, Solid1
1CompletedTreatmentRenal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRenal Cell Adenocarcinoma2
1CompletedTreatmentSarcomas / Tumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific3
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAnaplastic Astrocytoma (AA) / Bithalamic High Grade Glioma / Brain Stem Gliomas / Diffuse Intrinsic Pontine Glioma (DIPG) / Glioblastomas / High Grade Glioma (HGG) / Malignant Glioma of Brain1
1RecruitingTreatmentCancer of the Ovary / Cancer, Breast1
1RecruitingTreatmentCancer, Breast / Tumors, Solid1
1RecruitingTreatmentCentral Nervous System Embryonal Tumor, Not Otherwise Specified / Malignant Gliomas / Recurrent Atypical Teratoid/Rhabdoid Tumor / Recurrent Childhood Ependymoma / Recurrent Diffuse Intrinsic Pontine Glioma / Recurrent Medulloblastoma / Refractory Diffuse Intrinsic Pontine Glioma1
1RecruitingTreatmentColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer / Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma / Colorectal Cancers / Non-small Cell Lung Carcinoma (Adenocarcinoma) / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentEverolimus / Neuroendocrine Tumors1
1RecruitingTreatmentHead and Neck Carcinoma / Lung Cancers1
1RecruitingTreatmentLeukaemia, Lymphoblastic / Lymphoma, Lymphoblastic1
1RecruitingTreatmentMalignant Neoplasm of Breast / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Neoplasms of Uncertain or Unknown Behavior1
1RecruitingTreatmentNeoplasms, Breast1
1RecruitingTreatmentProstate Cancer Patients With Detectable PSA Following Prostatectomy1
1RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentRenal Cell Carcinoma Recurrent1
1RecruitingTreatmentTransplantation, Liver1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1TerminatedNot AvailableCancers1
1TerminatedTreatment714leukemia / Malignant Lymphomas1
1TerminatedTreatmentCancer, Breast2
1TerminatedTreatmentCancers1
1TerminatedTreatmentGraft Versus Host Disease (GVHD)1
1TerminatedTreatmentHead and Neck Carcinoma2
1TerminatedTreatmentHepatocellular,Carcinoma1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1TerminatedTreatmentLung Cancers / Metastatic Cancers1
1TerminatedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentMultiple Myeloma in Relapse1
1TerminatedTreatmentNeoplasm Metastases / Neuroendocrine Tumors / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentRenal Cell Adenocarcinoma2
1Unknown StatusTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1Unknown StatusTreatmentLeukemias1
1Unknown StatusTreatmentLocally Advanced Disease / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1Unknown StatusTreatmentMetastatic or Locally Advanced Solid Tumors1
1WithdrawnTreatmentCervical Cancers1
1WithdrawnTreatmentLiver Cancer1
1WithdrawnTreatmentRecurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Tongue Cancer1
1, 2Active Not RecruitingTreatmentAdenocarcinomas / Neoplasms, Pancreatic1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / B-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / Waldenström's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors2
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentCentral Nervous System Metastases / Her2-Positive Breast Cancer / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2Active Not RecruitingTreatmentHistological Evidence of Metastatic Clear Cell Renal Cell Carcinoma / Metastatic Clear Cell Renal Cell Carcinoma / Of Discontinuing Sunitinib, Sorafenib or Pazopanib. Previous / That Has Been Previously Treated With 1-3 Prior Regimens. Phase 1 Only, Any Number of Prior Regimens / Therapy With Bevacizumab, IL2, or Interferon Are Permitted / With Evidence of Progressive Disease on or Within 6 Months1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
1, 2Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1, 2Active Not RecruitingTreatmentProgressive Neuroendocrine Tumors of pancreatic origin1
1, 2Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
1, 2CompletedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Stage IV Esophageal Cancer1
1, 2CompletedTreatmentAdult Synovial Sarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
1, 2CompletedTreatmentAdvanced or Metastatic Pancreatic Adenocarcinoma1
1, 2CompletedTreatmentAgnogenic Myeloid Metaplasia / Leukemias / Mantle Cell Lymphoma (MCL)1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentAngiolipoma / Tuberous Sclerosis1
1, 2CompletedTreatmentBladder Cancers1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Prostate Cancer1
1, 2CompletedTreatmentCD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
1, 2CompletedTreatmentCancers of the Head and Neck / Neoplasms, Head and Neck1
1, 2CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
1, 2CompletedTreatmentEpilepsies / Tuberous Sclerosis Complex (TSC)1
1, 2CompletedTreatmentGastrointestinal Cancers1
1, 2CompletedTreatmentGastrointestinal Stromal Tumors1
1, 2CompletedTreatmentHead and Neck Carcinoma1
1, 2CompletedTreatmentHepatocellular,Carcinoma1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2CompletedTreatmentLeukemia, Lymphocytic1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentLung Cancers1
1, 2CompletedTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMetastatic Gastric Cancers1
1, 2CompletedTreatmentMetastatic Renal Cell Cancer1
1, 2CompletedTreatmentMetastatic, Androgen Independent Prostate Cancer / Prostate Cancer1
1, 2CompletedTreatmentPancreatic Cancer Metastatic1
1, 2CompletedTreatmentProstate Cancer1
1, 2CompletedTreatmentRenal Cancers1
1, 2CompletedTreatmentRenal Cell Adenocarcinoma1
1, 2CompletedTreatmentSubependymal Giant Cell Astrocytoma / Tuberous Sclerosis1
1, 2Not Yet RecruitingTreatmentTransplantation, Liver1
1, 2RecruitingTreatmentAcute Coronary Syndromes (ACS)1
1, 2RecruitingTreatmentAdult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Transplant, Kidney1
1, 2RecruitingTreatmentAnaplastic Gliomas / Glioblastomas / Neoplasms, Brain1
1, 2RecruitingTreatmentCancer, Breast2
1, 2RecruitingTreatmentChildren, Adolescents and Young Adults With Refractory or Recurrent Malignancies1
1, 2RecruitingTreatmentColorectal Adenocarcinoma (CRC) / Gastric Adenocarcinoma / Renal Cell Adenocarcinoma / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentHormone Receptor (HR)-Positive Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
1, 2RecruitingTreatmentLymphoma, Hodgkins1
1, 2RecruitingTreatmentNeuroendocrine Carcinomas1
1, 2RecruitingTreatmentPTEN gene mutation / PTEN Hamartoma Tumor Syndrome1
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2RecruitingTreatmentProgeria1
1, 2RecruitingTreatmentRecurrent and Refractory Solid Tumors1
1, 2SuspendedTreatmentAdvanced Solid Tumors1
1, 2TerminatedTreatmentCancer of the Ovary / Cancers / Malignant Neoplasm of Colon / Neuroendocrine1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Cancer, Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2TerminatedTreatmentHead and Neck Carcinoma2
1, 2TerminatedTreatmentLiver Cancer1
1, 2TerminatedTreatmentLung Cancers1
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentNeoplasms1
1, 2Unknown StatusTreatmentAdvanced Malignancies1
1, 2Unknown StatusTreatmentCarcinoid Tumors / Neuroendocrine Tumors1
1, 2Unknown StatusTreatmentEnd-Stage Renal Disease (ESRD) / Renal Failure1
1, 2Unknown StatusTreatmentHematologic Diseases1
1, 2Unknown StatusTreatmentHepatocellular,Carcinoma1
1, 2WithdrawnTreatmentChronic Myeloid Leukemia (CML)1
2Active Not RecruitingPreventionGliomas1
2Active Not RecruitingPreventionRespiratory Tract Infections (RTI)1
2Active Not RecruitingTreatmentAcoustic Schwannoma / Neurofibromatosis Type 21
2Active Not RecruitingTreatmentAdvanced, Persistent, or Recurrent Endometrial Cancer1
2Active Not RecruitingTreatmentBladder Cancers / Metastatic Transitional Cell Carcinoma1
2Active Not RecruitingTreatmentBladder Carcinoma / Transitional Cell Carcinoma1
2Active Not RecruitingTreatmentCD20+, B-cell Lymphomas / Gray Zone Lymphoma / Hodgkins Disease (HD) / Mantle Cell Lymphoma (MCL) / Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL) / Transformed Lymphoma/DLBCL/PMBCL1
2Active Not RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentCancer, Breast6
2Active Not RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentClear-cell Metastatic Renal Cell Carcinoma1
2Active Not RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
2Active Not RecruitingTreatmentEndometrial Cancers2
2Active Not RecruitingTreatmentEndometrial Carcinoma / Malignant Neoplasms of Female Genital Organs1
2Active Not RecruitingTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentFibrolamellar Carcinoma / Fibrolamellar Liver Cancer1
2Active Not RecruitingTreatmentGastrin-Producing Neuroendocrine Tumor / Malignant Pancreatic Gastrinoma / Malignant Pancreatic Glucagonoma / Malignant Pancreatic Insulinoma / Malignant Pancreatic Somatostatinoma / Pancreatic Alpha Cell Adenoma / Pancreatic Beta Cell Adenoma / Pancreatic Delta Cell Adenoma / Pancreatic G-Cell Adenoma / Pancreatic Gastrinoma / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Neuroendocrine Tumor G1 / Pancreatic Neuroendocrine Tumor G2 / Pancreatic Polypeptide Tumor / Pancreatic Vipoma / Recurrent Pancreatic Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Somatostatin-Producing Neuroendocrine Tumor / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentGastrointestinal Neuroendocrine Tumors / Gastrointestinal Tumors / Pancreatic Tumors / Progressive Neuroendocrine Tumors of pancreatic origin1
2Active Not RecruitingTreatmentHead and Neck Carcinoma2
2Active Not RecruitingTreatmentHepatic Metastases / Metastases / Neuroendocrine Tumors1
2Active Not RecruitingTreatmentHormone Receptor Positive Breast Cancer1
2Active Not RecruitingTreatmentMalignant Peripheral Nerve Sheath Tumour (MPNST) / MPNST / Sarcomas1
2Active Not RecruitingTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Serous Surface Papillary Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
2Active Not RecruitingTreatmentMelanoma (Skin)1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentMetastatic Renal Cell Cancer / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
2Active Not RecruitingTreatmentNeoplasms1
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentMTor Protein / Neoplasms, Breast1
2Active Not RecruitingTreatmentNeuroendocrine Carcinoma of the Lung and Thymus1
2Active Not RecruitingTreatmentProstate Cancer1
2Active Not RecruitingTreatmentRenal Cancers2
2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma2
2Active Not RecruitingTreatmentThymoma and Thymic Carcinoma1
2Active Not RecruitingTreatmentThyroid Cancers2
2Active Not RecruitingTreatmentTransplantation, Kidney1
2Active Not RecruitingTreatmentTuberous Sclerosis1
2Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
2CompletedNot AvailableClear Cell Renal Cell Carcinoma / Clear-cell Metastatic Renal Cell Carcinoma1
2CompletedPreventionAdvanced Breast Cancer1
2CompletedPreventionHighly-sensitized Kidney Transplant Recipients1
2CompletedTreatmentAdenocarcinomas / Carcinoma NOS / Hypernephroid / Nephroid Carcinoma / Renal Cell / Renal Cell Adenocarcinoma1
2CompletedTreatmentAdenocarcinomas / Carcinoma NOS / Non Clear Cell Renal Carcinoma / Papillary Cell Renal Carcinoma / Renal Cell1
2CompletedTreatmentAdvanced Adult Hepatocellular Carcinoma1
2CompletedTreatmentAdvanced Gastric Cancer1
2CompletedTreatmentAdvanced Non-clear Cell Renal Cell Carcinoma1
2CompletedTreatmentAstrocytomas / Gliomas / Low-Grade Gliomas1
2CompletedTreatmentAstrocytomas / Low-Grade Gliomas / Oligoastrocytoma, Mixed / Oligodendrogliomas1
2CompletedTreatmentAutism, Early Infantile / Self-injury / Tuberous Sclerosis Complex (TSC)1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
2CompletedTreatmentCancer, Breast5
2CompletedTreatmentCancers1
2CompletedTreatmentCarcinoids / Carcinoma NOS / Neuroendocrine / Non Functioning / Non Functioning Neuroendocrine Tumors/NET / Non Syndromic Neuroendocrine Tumors/NET1
2CompletedTreatmentCarcinoma of Unknown Primary Origin1
2CompletedTreatmentCarcinoma, Adenoid Cystic1
2CompletedTreatmentCarcinoma, Islet Cell / Neoplasms, Pancreatic / Neuroendocrine Carcinomas / Neuroendocrine Tumors1
2CompletedTreatmentCarcinoma, Islet Cell / Neuroendocrine Carcinomas1
2CompletedTreatmentClear Cell Renal Cell Carcinoma1
2CompletedTreatmentColorectal Adenocarcinoma1
2CompletedTreatmentColorectal Cancers2
2CompletedTreatmentCondition After Allogenic Peripheral Stem Cell Transplantation (SCT)1
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2CompletedTreatmentExtra-Adrenal Paraganglioma / Non-functioning Carcinoid / Pheochromocytomas1
2CompletedTreatmentGerm Cell Cancer / Testicular Cancer1
2CompletedTreatmentGerm Cell Tumors1
2CompletedTreatmentGlioblastoma Multiforme (GBM)1
2CompletedTreatmentHER-2 Positive Breast Cancer1
2CompletedTreatmentHead and Neck Carcinoma2
2CompletedTreatmentHepatocellular,Carcinoma2
2CompletedTreatmentHer2-negative Locally Advanced Breast Cancer / Her2-negative Metastatic Breast Cancer1
2CompletedTreatmentHormone Refractory Prostate Cancer1
2CompletedTreatmentLeukemias / Lymphoproliferative Disorders / Malignant Lymphomas1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentLymphangioleiomyomatosis1
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
2CompletedTreatmentMantle Cell Lymphoma (MCL)1
2CompletedTreatmentMarginal Zone B-Cell Lymphoma1
2CompletedTreatmentMelanoma (Skin)2
2CompletedTreatmentMetastatic Bone Sarcomas / Relapsed Osteosarcoma1
2CompletedTreatmentMetastatic Breast Cancer (MBC)2
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentMetastatic Gastric Cancers1
2CompletedTreatmentMetastatic Melanoma2
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Gastrointestinal1
2CompletedTreatmentNeuroendocrine Carcinomas1
2CompletedTreatmentNeurofibromatoses / Neurofibromatosis Type 1 / Plexiform Neurofibroma1
2CompletedTreatmentNeurofibromatosis 11
2CompletedTreatmentNeurofibromatosis 21
2CompletedTreatmentNeurofibromatosis Type II1
2CompletedTreatmentPolycystic Liver Disease (PLD)1
2CompletedTreatmentProgressive Sarcoma1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentRenal Cancers2
2CompletedTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
2CompletedTreatmentRenal Cell Adenocarcinoma5
2CompletedTreatmentSarcoma, Bone / Soft Tissue Sarcoma (STS)1
2CompletedTreatmentSolid Malignancies / Tumors, Solid1
2CompletedTreatmentStomach Neoplasms2
2CompletedTreatmentSystemic Mastocytosis1
2CompletedTreatmentTransitional Cell Carcinoma1
2CompletedTreatmentTransplantation, Kidney2
2CompletedTreatmentTransplantation, Renal1
2CompletedTreatmentTuberous Sclerosis Complex (TSC)1
2CompletedTreatmentTumors, Solid1
2CompletedTreatmentUrothelial Cancer1
2CompletedTreatmentUveal Melanoma1
2CompletedTreatmentUveitis1
2Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Not Yet RecruitingTreatmentRenal Cell Adenocarcinoma1
2RecruitingPreventionGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentAdvanced Breast Cancer1
2RecruitingTreatmentBreast Cancer Stage IIB1
2RecruitingTreatmentCancer of the Ovary / Endometrial Cancers1
2RecruitingTreatmentCancer, Breast3
2RecruitingTreatmentCholangiocarcinoma of the Extrahepatic Bile Duct / Gallbladder Cancer1
2RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2RecruitingTreatmentEndometrial Cancers1
2RecruitingTreatmentEpilepsies / Focal Cortical Dysplasia / Tuberous Sclerosis Complex (TSC)1
2RecruitingTreatmentEstrogen Receptor Positive Breast Cancer1
2RecruitingTreatmentGliomas1
2RecruitingTreatmentHER2-negative Circulating Tumor Cells / HER2-negative Und Hormone-receptor Positive Metastatic Breast Cancer / Postmenopausal Female Patients1
2RecruitingTreatmentLow Grade Glioma (LGG) / Oligoastrocytoma, Mixed / Oligodendrogliomas / WHO Grade II Astrocytomas1
2RecruitingTreatmentMalignant Solid Neoplasms1
2RecruitingTreatmentMelanoma / Neoplasms Metastasis / TOR Serine-Threonine Kinases1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentNeoplasms, Brain1
2RecruitingTreatmentNeuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 / Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3 / Neuroendocrine Carcinoma, Grade 3 / Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) / Poorly Differentiated Malignant Neuroendocrine Carcinoma / Poorly Differentiated Neuroendocrine Carcinoma1
2RecruitingTreatmentNeuroendocrine Carcinomas3
2RecruitingTreatmentNeuroendocrine Carcinomas / Neuroendocrine Neoplasms / Neuroendocrine Tumors / Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas1
2RecruitingTreatmentNeuroendocrine Tumors1
2RecruitingTreatmentNon Clear Cell Renal Cell Carcinoma (nccRCC)1
2RecruitingTreatmentOrthotopic Liver Transplant1
2RecruitingTreatmentPediatric Progressive Low-grade Gliomas / Pediatric Recurrent Progressive Low-grade Gliomas1
2RecruitingTreatmentPrimary Aldosteronism1
2RecruitingTreatmentRare Tumor / Refractory Tumors1
2RecruitingTreatmentRecurrent Childhood Ependymoma1
2RecruitingTreatmentRecurrent Meningiomas / Resistant Meningiomas1
2RecruitingTreatmentRefractory Hurthle Cell Thyroid Cancer1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentRenal Cell Adenocarcinoma1
2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2RecruitingTreatmentSporadic Angiomyolipomas (AMLs)1
2RecruitingTreatmentMTOR / TSC1 / TSC2 / Tuberous Sclerosis Complex (TSC)1
2RecruitingTreatmentThyroid Cancers1
2RecruitingTreatmentTuberculosis1
2SuspendedTreatmentChondrosarcomas1
2TerminatedPreventionRenal Cancers1
2TerminatedTreatmentAge-Related Macular Degeneration (ARMD) / Choroidal Neo-Vascular Age-onset Macular Degeneration1
2TerminatedTreatmentBirt-Hogg-Dube Syndrome / Chromophobe Renal Cell Carcinoma / Renal Cancers1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCastrate Resistant Prostate Cancer (CRPC) / Chemotherapy Naive Prostate Cancer / Prostate Cancer1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentCutaneous T-Cell Lymphoma (CTCL)1
2TerminatedTreatmentEndocrine Breast Diseases / Neoplasms Metastasis / Neoplasms, Breast1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / Gastrinoma / Glucagonoma / HER2-Negative Breast Cancer / Insulinoma / Mucositis / Oral Complications / Pancreatic Polypeptide Tumor / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Recurrent Islet Cell Carcinoma / Renal Cell Cancer, Recurrent / Somatostatinoma / Stage III Renal Cell Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Renal Cell Cancer1
2TerminatedTreatmentGastrinoma / Glucagonoma / Hepatic Metastases / Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Somatostatinoma1
2TerminatedTreatmentGlioblastoma Multiforme (GBM)1
2TerminatedTreatmentIntracranial Meningioma1
2TerminatedTreatmentIslet Cell Tumor1
2TerminatedTreatmentKaposi s Sarcoma (KS)1
2TerminatedTreatmentKidney (Renal Cell) Cancer / Neoplasms, Kidney1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMetastatic Clear Cell Renal Carcinoma1
2TerminatedTreatmentMetastatic Melanoma1
2TerminatedTreatmentMetastatic Renal Cancer1
2TerminatedTreatmentMetastatic Renal Cell Carcinoma1
2TerminatedTreatmentMyelodysplastic Syndromes1
2TerminatedTreatmentPeutz-Jeghers Syndrome (PJS)1
2TerminatedTreatmentPlexiform Neurofibroma Associated With Neurofibromatosis Type 11
2TerminatedTreatmentProgressive Neuroendocrine Tumors of pancreatic origin1
2TerminatedTreatmentRecurrent Hepatitis C1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentCholangiocarcinomas2
2Unknown StatusTreatmentHead and Neck Carcinoma1
2Unknown StatusTreatmentHepatic Failure / Liver Cirrhosis / Liver Diseases / Neoplasms, Hepatic1
2Unknown StatusTreatmentHormone Receptor Positive Malignant Neoplasm of Breast1
2Unknown StatusTreatmentKidney Diseases1
2Unknown StatusTreatmentMesothelioma, Malignant1
2Unknown StatusTreatmentNeoplasms, Breast1
2Unknown StatusTreatmentNeuroendocrine Tumors1
2Unknown StatusTreatmentProstate Cancer2
2Unknown StatusTreatmentRefractory or Relapsed Osteosarcoma1
2Unknown StatusTreatmentRefractory or Relapsed RMS and Soft Tissue Sarcomas1
2Unknown StatusTreatmentRenal Insufficiency,Chronic / Transplantation, Liver1
2WithdrawnTreatmentCancer, Breast3
2WithdrawnTreatmentLocally Metastatic Malignant Neoplasm1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentNeoplasms Metastasis / Neoplastic Processes / Peutz-Jeghers Syndrome (PJS)1
2WithdrawnTreatmentSegmental Overgrowth Syndrome1
2WithdrawnTreatmentSturge Weber Syndrome1
2, 3Active Not RecruitingTreatmentUterine Cancers1
2, 3Not Yet RecruitingTreatmentFacial Angiofibromas1
2, 3RecruitingTreatmentRenal Cell Cancer Metastatic1
2, 3RecruitingTreatmentTSC Related Autism / TSC Related Cognitive Disability / TSC Related Learning Problems / Tuberous Sclerosis Complex (TSC)1
2, 3TerminatedTreatmentDelayed Graft Function1
2, 3TerminatedTreatmentGraft Versus Host Disease (GVHD)1
2, 3TerminatedTreatmentPolycystic Kidney Diseases1
3Active Not RecruitingTreatmentAdvanced Gastric Cancer / Esophagogastric Junction Cancer1
3Active Not RecruitingTreatmentAdvanced NET of GI Origin / Advanced NET of Lung Origin / Neuroendocrine Tumors1
3Active Not RecruitingTreatmentAdvanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma1
3Active Not RecruitingTreatmentBreast Cancer Metastatic1
3Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V71
3Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3Active Not RecruitingTreatmentPost Menopausal Breast Cancer1
3Active Not RecruitingTreatmentPrevention of Acute Rejection in Paediatric Recipients of a Renal Transplant1
3Active Not RecruitingTreatmentRenal Cancers1
3Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
3CompletedBasic ScienceHepatitis C Recurrence After Liver Transplant1
3CompletedPreventionCardiac Transplantation1
3CompletedPreventionDe Novo Kidney Transplant Recipients / Transplantation, Renal1
3CompletedPreventionHeart Transplantation1
3CompletedPreventionLymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedPreventionRejection, Transplant1
3CompletedPreventionTransplantation, Kidney2
3CompletedPreventionTransplantation, Renal3
3CompletedTreatmentAdvanced Gastric Cancer1
3CompletedTreatmentAdvanced Neuroendocrine Tumors of Pancreatic Origin1
3CompletedTreatmentCancer, Breast3
3CompletedTreatmentCarcinoid Tumors / Malignant Carcinoid Syndrome1
3CompletedTreatmentCarcinoma NOS1
3CompletedTreatmentDe Novo Renal Transplantation1
3CompletedTreatmentHER2/Neu Over-expressing Locally Advanced Breast Cancer / Metastatic Breast Cancer (MBC)1
3CompletedTreatmentHeart Transplantation1
3CompletedTreatmentLiver Transplant Recipients1
3CompletedTreatmentLymphangioleiomyomatosis (LAM) / Tuberous Sclerosis Complex (TSC)1
3CompletedTreatmentMetastatic Breast Cancer (MBC)1
3CompletedTreatmentMetastatic Renal Cell Carcinoma1
3CompletedTreatmentOrgan Transplantation, Renal Transplantation1
3CompletedTreatmentRejection, Transplant1
3CompletedTreatmentRejection, Transplant / Transplantation, Kidney1
3CompletedTreatmentRenal Interstitial Fibrosis1
3CompletedTreatmentSubependymal Giant Cell Astrocytoma / Tuberous Sclerosis1
3CompletedTreatmentTransplant, Kidney2
3CompletedTreatmentTransplant; Failure, Kidney1
3CompletedTreatmentTransplantation, Kidney2
3CompletedTreatmentTransplantation, Liver4
3CompletedTreatmentTransplantation, Lung2
3CompletedTreatmentTransplantation, Renal2
3CompletedTreatmentTuberous Sclerosis Complex-associated Refractory Seizures1
3Not Yet RecruitingPreventionTransplantation, Liver1
3Not Yet RecruitingTreatmentEpilepsy and Focal Cortical Dysplasia II1
3Not Yet RecruitingTreatmentProstate Cancer1
3RecruitingTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3RecruitingTreatmentCancer, Breast2
3RecruitingTreatmentCancer, Breast / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Locally Advanced Malignant Neoplasm / Metastatic Breast Cancer (MBC)1
3RecruitingTreatmentCardiac Allograft Vasculopathy / Chronic Kidney Disease (CKD) / Heart Transplant Failure and Rejection / Heart Transplant Infection / Immunosuppression / Pediatric Heart Transplantation / Post-Transplant Lymphoproliferative Disorder1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentNeuroendocrine Tumors1
3RecruitingTreatmentNeuroendocrine Tumors / Progressive Neuroendocrine Tumors of pancreatic origin1
3RecruitingTreatmentPrimary Non-metastatic Breast Cancer / Who Remain Disease-free / Who Remain Disease-free After Receiving at Least 1 Year of Adjuvant Hormone Therapy1
3RecruitingTreatmentRenal Cell Adenocarcinoma1
3RecruitingTreatmentTransplantation, Liver1
3RecruitingTreatmentTuberous Sclerosis Complex (TSC)1
3SuspendedTreatmentCancer, Breast1
3TerminatedTreatmentChronic Renal Failure (CRF)1
3TerminatedTreatmentMetastatic Breast Cancer (MBC)1
3Unknown StatusTreatmentCardiac Transplantation / Skin Cancers1
3Unknown StatusTreatmentCoronary Artery Disease / Coronary Artery Restenosis1
4Active Not RecruitingNot AvailableGrowth and Development1
4Active Not RecruitingBasic ScienceHuman Immunodeficiency Virus (HIV) / Transplant, Kidney / Transplantation, Liver1
4Active Not RecruitingPreventionInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentCytomegalovirus / Transplantation, Kidney1
4Active Not RecruitingTreatmentInfections, Cytomegalovirus / Transplantation Infection1
4CompletedNot AvailableFunction of Renal Transplant1
4CompletedDiagnosticCardiac Transplant1
4CompletedOtherHER2/Neu-negative Carcinoma of Breast / Hormone Receptor Positive Malignant Neoplasm of Breast / Recurrent Breast Cancer1
4CompletedOtherRenal Failure1
4CompletedOtherTransplant, Kidney1
4CompletedPreventionCardiac Transplantation1
4CompletedPreventionChronic Rejection of Cardiac Transplant1
4CompletedPreventionDisorder Related to Cardiac Transplantation1
4CompletedPreventionHeart Transplantation1
4CompletedPreventionTransplantation, Kidney1
4CompletedPreventionTransplantation, Renal3
4CompletedSupportive CareHepatitis C Viral Infection / Renal Allograft1
4CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
4CompletedTreatmentBK Virus Infection1
4CompletedTreatmentCarcinoma, Large Cell / Neuroendocrine Tumors1
4CompletedTreatmentCardiac Transplantation / Renal Insufficiency,Chronic1
4CompletedTreatmentChronic Allograft Dysfunction in Renal Transplantation1
4CompletedTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentComparative Study / Immunosuppressive Agents1
4CompletedTreatmentFailure of Exactly One Prior VEGF-targeted Therapy / Metastatic Renal Cell Carcinoma1
4CompletedTreatmentHeart Transplantation2
4CompletedTreatmentInfections, Cytomegalovirus / Renal Transplant Failure / Transplant; Complication, Rejection1
4CompletedTreatmentInterstitial Fibrosis (IF) / Transplant dysfunction1
4CompletedTreatmentKidney Transplantation, Renal Transplantation1
4CompletedTreatmentLocally Advanced Metastatic Breast Cancer / Locally Advanced or Metastatic Breast Cancer / Metastatic Breast Cancer (MBC) / Postmenopausal Women1
4CompletedTreatmentMetastatic Renal Cell Carcinoma1
4CompletedTreatmentMetastatic Renal Cell Carcinoma (mRCC)1
4CompletedTreatmentNeuroendocrine Tumors1
4CompletedTreatmentOestrogen Receptor Positive Advanced Breast Cancer1
4CompletedTreatmentPlanned Kidney Transplantation1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRenal Function and Chronic Allograft Vasculopathy1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentTransplant, Kidney1
4CompletedTreatmentTransplantation, Kidney1
4CompletedTreatmentTransplantation, Organ1
4CompletedTreatmentTransplantation, Renal3
4Not Yet RecruitingTreatmentBK Virus Nephropathy After Kidney Transplantation1
4Not Yet RecruitingTreatmentDisorder Related to Renal Transplantation / Immunosuppression Related Infectious Disease / Virus Diseases1
4Not Yet RecruitingTreatmentRenal Angiomyolipomas1
4RecruitingNot AvailableLeft Ventricular Hypertrophy1
4RecruitingOtherTransplantation, Liver1
4RecruitingPreventionKidney Transplant Infection1
4RecruitingTreatmentChronic Renal Failure (CRF) / Graft Failure / Kidney Transplant Rejection / Transplant; Failure, Kidney1
4RecruitingTreatmentDrug Interaction Potentiation / Transplantation, Kidney1
4RecruitingTreatmentGastrointestinal Disorder, Functional / Kidney Transplant Rejection1
4RecruitingTreatmentHepatocellular,Carcinoma1
4RecruitingTreatmentLeft Ventricular Hypertrophy1
4RecruitingTreatmentNeoplasms1
4RecruitingTreatmentProgressive Neuroendocrine Tumors of pancreatic origin1
4RecruitingTreatmentRenal Cell Adenocarcinoma1
4RecruitingTreatmentTransplant, Kidney1
4TerminatedBasic ScienceDisorder Related to Renal Transplantation / Exercise, Aerobic / Strength, Muscle1
4TerminatedOtherRenal Cell Adenocarcinoma1
4TerminatedPreventionHeart Transplantation / Renal Function Abnormal1
4TerminatedPreventionImpaired Renal Function1
4TerminatedPreventionTransplantation, Renal1
4TerminatedTreatmentTransplantation, Renal2
4Unknown StatusPreventionDisorder Related to Renal Transplantation1
4Unknown StatusPreventionHeart Transplantation / Kidney Diseases1
4Unknown StatusPreventionImmunosuppression / Transplantation, Homologous1
4Unknown StatusPreventionKidney Transplant Recipients1
4Unknown StatusPreventionKidney; Complications, Allograft1
4Unknown StatusTreatmentCardiac Transplant1
4Unknown StatusTreatmentDelayed Function of Renal Transplant1
4Unknown StatusTreatmentImmunosuppression / Transplant, Kidney1
4Unknown StatusTreatmentInfections, Cytomegalovirus1
4Unknown StatusTreatmentTransplantation, Renal1
4WithdrawnNot AvailableTransplantation, Kidney1
4WithdrawnTreatmentTransplantation, Kidney1
Not AvailableActive Not RecruitingDiagnosticAdvanced Solid Tumors / Cancers1
Not AvailableActive Not RecruitingOtherHormone Receptor Positive Malignant Neoplasm of Breast / Metastatic Breast Cancer (MBC)1
Not AvailableActive Not RecruitingPreventionRenal Failure1
Not AvailableActive Not RecruitingTreatmentEnd Stage Renal Failure With Renal Transplant1
Not AvailableActive Not RecruitingTreatmentRecurrent Childhood Brain Tumor1
Not AvailableAvailableNot AvailableGastrointestinal Stromal Tumors1
Not AvailableCompletedNot AvailableCancer, Breast1
Not AvailableCompletedNot AvailableCancer, Breast / Renal Cell Adenocarcinoma1
Not AvailableCompletedNot AvailableNeuroendocrine Tumors1
Not AvailableCompletedBasic ScienceDifference of 12-hour AUC1
Not AvailableCompletedOtherUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentHigh Model for End-Stage Liver Disease (MELD) Score1
Not AvailableCompletedTreatmentRenal Cell Adenocarcinoma1
Not AvailableCompletedTreatmentTransplantation, Kidney1
Not AvailableNo Longer AvailableNot AvailableMetastatic Renal Cell Cancer1
Not AvailableRecruitingNot AvailableEnd Stage Liver Diseases1
Not AvailableRecruitingNot AvailableHepatocellular,Carcinoma / Neuroendocrine Tumors1
Not AvailableRecruitingNot AvailableLymphangioleiomyomatosis1
Not AvailableRecruitingNot AvailablePancreatic Neuroendocrine Tumor, Well Differentiated and Progressive1
Not AvailableRecruitingBasic ScienceNeoplasms1
Not AvailableRecruitingTreatmentGastrointestinal Cancers1
Not AvailableRecruitingTreatmentImmunosuppression1
Not AvailableSuspendedTreatmentAdvanced Malignant Solid Neoplasm / Neoplasms / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Solid Neoplasm1
Not AvailableTerminatedTreatmentEnd Stage Renal Failure With Renal Transplant1
Not AvailableUnknown StatusTreatmentCalcineurin Inhibitor Toxicity / Chronic Allograft Injury1
Not AvailableUnknown StatusTreatmentTransplant, Kidney1
Not AvailableUnknown StatusTreatmentMicroRNA Profiles1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Chunghwa Chemical Synthesis and Biotech Co. Ltd.
  • Novartis AG
  • Quality Care
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral10 mg
TabletOral2.5 mg/1
TabletOral2.5 mg
TabletOral5 mg/1
TabletOral5 mg
TabletOral7.5 mg/1
TabletOral7.5 mg
Tablet, for suspensionOral2 mg/1
Tablet, for suspensionOral2 mg
Tablet, for suspensionOral3 mg
Tablet, for suspensionOral3 mg/1
Tablet, for suspensionOral5 mg
Tablet, for suspensionOral5 mg/1
TabletOral0.25 mg
TabletOral0.50 mg
TabletOral0.75 mg
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral.75 mg/1
Prices
Unit descriptionCostUnit
Afinitor 10 mg tablet247.58USD tablet
Afinitor 5 mg tablet234.75USD tablet
Vesicare 10 mg tablet6.98USD tablet
Vesicare 5 mg tablet6.98USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6440990No1993-09-242013-09-24Us
CA2145383No2004-11-162013-09-24Canada
CA2225960No2004-05-112016-07-12Canada
US8410131Yes2006-05-012026-05-01Us
US8436010Yes2002-08-222022-08-22Us
US5665772Yes2000-03-092020-03-09Us
US6004973Yes1997-01-122017-01-12Us
US6239124Yes1998-02-112018-02-11Us
US6455518Yes1998-01-292018-01-29Us
US8778962Yes2002-08-182022-08-18Us
US9006224No2008-07-012028-07-01Us
US7741338No1999-12-062019-12-06Us
US7297703Yes2000-06-062020-06-06Us
US8617598Yes2003-03-272023-03-27Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00163 mg/mLALOGPS
logP5.01ALOGPS
logP7.4ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area204.66 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity261.71 m3·mol-1ChemAxon
Polarizability106.61 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8288
Blood Brain Barrier-0.9541
Caco-2 permeable-0.6604
P-glycoprotein substrateSubstrate0.8117
P-glycoprotein inhibitor IInhibitor0.7789
P-glycoprotein inhibitor IIInhibitor0.7294
Renal organic cation transporterNon-inhibitor0.796
CYP450 2C9 substrateNon-substrate0.8793
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9078
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9388
CYP450 2C19 inhibitorNon-inhibitor0.9346
CYP450 3A4 inhibitorNon-inhibitor0.8168
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9734
Ames testNon AMES toxic0.6227
CarcinogenicityNon-carcinogens0.9362
BiodegradationNot ready biodegradable0.9257
Rat acute toxicity2.7442 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9776
hERG inhibition (predictor II)Non-inhibitor0.712
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (87.7 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolide lactams
Sub Class
Not Available
Direct Parent
Macrolide lactams
Alternative Parents
Alpha amino acid esters / Macrolides and analogues / Piperidines / Oxanes / Tertiary carboxylic acid amides / Secondary alcohols / Carboxylic acid esters / Cyclic ketones / Hemiacetals / Lactams
show 10 more
Substituents
Macrolide lactam / Alpha-amino acid ester / Macrolide / Alpha-amino acid or derivatives / Piperidine / Oxane / Tertiary carboxylic acid amide / Carboxamide group / Carboxylic acid ester / Hemiacetal
show 23 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
cyclic ketone, secondary alcohol, ether, primary alcohol, lactam, macrocyclic lactone, cyclic acetal (CHEBI:68478)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tfiiic-class transcription factor binding
Specific Function
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly...
Gene Name
MTOR
Uniprot ID
P42345
Uniprot Name
Serine/threonine-protein kinase mTOR
Molecular Weight
288889.05 Da
References
  1. Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM: Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Pediatr Transplant. 2008 Jun;12(4):456-63. doi: 10.1111/j.1399-3046.2007.00832.x. [PubMed:18466433]
  2. Rostaing L, Kamar N: mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol. 2010 Mar-Apr;23(2):133-42. [PubMed:20155724]
  3. George S, Bukowski RM: Role of everolimus in the treatment of renal cell carcinoma. Ther Clin Risk Manag. 2009 Oct;5(5):699-706. Epub 2009 Sep 15. [PubMed:19774211]
  4. Teachey DT, Grupp SA, Brown VI: Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16. [PubMed:19344392]
  5. Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E: New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. [PubMed:20569080]
  6. Coppin C: Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics. 2010 May 25;4:91-101. [PubMed:20531964]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Picard N, Levoir L, Lamoureux F, Yee SW, Giacomini KM, Marquet P: Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica. 2011 Sep;41(9):752-7. doi: 10.3109/00498254.2011.573882. Epub 2011 Apr 27. [PubMed:21524191]
  2. Votubia, INN:EVEROLIMUS - European Medicines Agency - europa.eu [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Picard N, Levoir L, Lamoureux F, Yee SW, Giacomini KM, Marquet P: Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica. 2011 Sep;41(9):752-7. doi: 10.3109/00498254.2011.573882. Epub 2011 Apr 27. [PubMed:21524191]
  2. Votubia, INN:EVEROLIMUS - European Medicines Agency - europa.eu [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Picard N, Levoir L, Lamoureux F, Yee SW, Giacomini KM, Marquet P: Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica. 2011 Sep;41(9):752-7. doi: 10.3109/00498254.2011.573882. Epub 2011 Apr 27. [PubMed:21524191]

Drug created on August 29, 2007 09:37 / Updated on August 15, 2018 09:51